The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.50
Bid: 1,796.00
Ask: 1,796.50
Change: 19.00 (1.07%)
Spread: 0.50 (0.028%)
Open: 1,784.00
High: 1,799.50
Low: 1,780.00
Prev. Close: 1,780.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

8 Jun 2016 11:11

Glaxo Says Rheumatoid Arthritis Treatment Meets Primary Endpoints

Read more
8 Jun 2016 08:57

GlaxoSmithKline Presents Positive Phase III Data For Benlysta

Read more
7 Jun 2016 22:01

J&J, GSK rheumatoid arthritis drug meets goals of large trial

June 7 (Reuters) - An experimental drug for rheumatoid arthritis developed by Johnson & Johnson and GlaxoSmithKline slowed joint damage and improved symptoms of the disease, meeting the main goals of a large, late stage trial, according to data released on Tuesday. In the study of 1,670 pat

Read more
6 Jun 2016 17:20

CORRECTED-Novartis study shows skin cancer combo also works on lungs

(Corrects paragraph one to show day of week Novartis said this was Monday, instead of Tuesday) * Novartis to seek approval after July following trial * Drug combo shrank tumours in 63 pct of patients in study * Combination already approved in skin cancer By John Miller

Read more
6 Jun 2016 14:04

UPDATE 1-U.S. top court rejects GSK bid to throw out racketeering lawsuits

(Adds details on dispute, paragraphs 3-7) By Lawrence Hurley WASHINGTON, June 6 (Reuters) - The U.S. Supreme Court on Monday declined to hear GlaxoSmithKline Plc's bid to throw out lawsuits by union health and welfare funds that said the company's misrepresentation of heart-related ri

Read more
6 Jun 2016 13:39

U.S. top court rejects GSK bid to throw out racketeering lawsuits

WASHINGTON, June 6 (Reuters) - The U.S. Supreme Court on Monday declined to hear GlaxoSmithKline Plc's bid to throw out lawsuits by union health and welfare funds that said the company's misrepresentation of heart-related risks of its diabetes medication Avandia caused them to pay too much for th

Read more
3 Jun 2016 15:41

UPDATE 2-Botswana gets GSK's modern HIV drug in largest ever Africa deal

* Tivicay to be used as first-line HIV treatment * 100,000 more Botswanans to receive drug treatment (Adds launch in Gaborone, comment from UNAIDS and U.S. ambassador) By Ben Hirschler LONDON, June 3 (Reuters) - An HIV drug first approved less than three years ago is being rol

Read more
3 Jun 2016 11:27

Glaxo To Present Sirukumab, Benlysta Data At Rheumatology Congress

Read more
3 Jun 2016 07:22

GSK's modern HIV drug to be rolled out in Botswana

LONDON, June 3 (Reuters) - An HIV drug first approved less than three years is to be rolled out in Botswana as a first-line core medicine to treat newly diagnosed patients under a contract agreed between the government and ViiV Healthcare. ViiV, which is majority-owned by GlaxoSmithKline, s

Read more
2 Jun 2016 12:45

Reuters Business News Schedule at 1230 GMT/0830 AM ET

Editor: Sonya Hepinstall +44 207 542 3479 Global Picture Desk: +65 6870 3775 Global Graphics Desk: +65 6870 3595 (All times GMT / ET) Receive this schedule by email: http://mediaexpress.reuters.com TOP STORIES ECB keeps rates unchanged, may raise inflatio

Read more
2 Jun 2016 08:00

UPDATE 1-GSK seeks lead in triple lung drug market with 2016 filing plan

* U.S. filing by end 2016 vs first half 2018 seen previously * Rivals in triple drug space include AstraZeneca, Novartis (Adds more details on competitive market) By Ben Hirschler LONDON, June 2 (Reuters) - GlaxoSmithKline moved to consolidate its lead in a new class of three-

Read more
2 Jun 2016 07:11

GlaxoSmithKline brings forward COPD application in US by over a year

(ShareCast News) - GlaxoSmithKline has, after discussions with the US regulator, accelerated the new drug application for its daily closed triple therapy for chronic obstructive pulmonary disease (COPD). GSK and its partner in the drug, Innoviva, now expect to make the US regulatory submission befor

Read more
2 Jun 2016 06:31

GSK to file 3-in-1 lung drug for U.S. approval this year

LONDON, June 2 (Reuters) - GlaxoSmithKline said on Thursday it now expects to file its new three-in-one inhaled lung drug for U.S. approval by the end of 2016, rather than the first half of 2018 as previously expected, in a boost for its pivotal respiratory business. The so-called "closed t

Read more
2 Jun 2016 06:23

GlaxoSmithKline Brings US Drug Application For COPD Therapy Forward

Read more
1 Jun 2016 23:01

Anti-graft group says drugmakers failing to tackle corruption

LONDON, June 2 (Reuters) - The global pharmaceuticals industry remains open to corruption abuse, despite a raft of scandals in recent years, with both companies and governments failing to tackle the issue adequately, according to Transparency International. The anti-corruption advocacy grou

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.